Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of AEM-28 in Healthy Subjects and Patients With Refractory Hypercholesterolemia

Next Previous
Search
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of AEM-28 in Healthy Subjects and Patients With Refractory Hypercholesterolemia

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 25 Jan 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AEM 28 (Primary)
  • Indications Hypercholesterolaemia
  • Focus Adverse reactions; First in man
  • Sponsors Capstone Therapeutics; LipimetiX

Most Recent Events

  • 30 Mar 2015 Status changed from recruiting to completed, according to to ClinicalTrials.gov record.
  • 02 Sep 2014 Top-line data are expected in late fourth quarter 2014 or early first quarter 2015, according to a Capstone Therapeutics media release.
  • 30 May 2014 New source identified and integrated (ClinicalTrials.gov: NCT02100839).

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top